New Delhi: The government said a total of 103 applications have approved central financial aid to MSME (Micro, SME) and hopes to upgrade to international standards, which has put a barrier to India’s Pharma Ompitions.
The entire financial support of the government-built drug technology upgrade assistance program is equivalent to ₹105 million.
According to the United Health Ministry, about 10,000 drug manufacturing companies in India are classified as micro and medium-sized enterprises (MSMES). However, only 2,000 people have a certificate of good manufacturing practice from the World Health Organization (WHO).
Read also | Guidelines for the creation of gene therapy for central drug modulators, biosimilar: DCGI
The plan was launched last year for pharmaceutical companies to modernize their units after a series of scandals surrounding India’s drug exports.
The government revised the timetable M under the Drugs and Cosmetics Act in 2023 to enable companies to follow good manufacturing practices (GMP), a critical step in ensuring the quality and safety of drugs produced in India.
“The revised revised Pharmaceutical Technology Upgrade Assistance Program (RPTUAS) began in September 2024 and approved 103 applications starting in November 2024. ₹A pharmaceutical spokesman said: “Pay $10.5 billion.”
Read also | India’s Eye Global Pharmaceutical Advantages and ₹50 million revitalization plan
So far, the two companies have completed the process.
In September 2024, the government strengthened financial incentives ₹10 million ₹Drug manufacturers upgrade their facilities by 20 million. Under this, the average income of the drug unit ₹10 million to less than ₹500 million will receive a 20% investment. Income companies ₹500 million to less than ₹Rs 25 billion qualify for 15% investment while income is ₹25 billion to less than ₹$5 billion is eligible for a 10% investment.
Provide incentives for expenditures incurred on items such as utilities, cleaning room facilities, testing labs, stabilization rooms, wastewater treatment/waste management and production equipment.
Read also | Indian pharmaceuticals bitter medicine as Trump tariffs could hurt exports $225 million
The spokesman said another 200 units had registered interest.
India’s manufacturing hubs include Himaal Pradesh, Madhya Pradesh, Hyderabad, Maharashtra and Gujarat, which belong to the state’s regulatory radar and central drug licensing authorities.
Earlier, in January, the government extended the GMP compliance for one year to MSME Pharmaceuticals.
India is the world’s largest supplier of generic drugs. According to the drug sector, the country produces about 60,000 generic drugs in 60 treatment categories, accounting for 20% of the global generic drug supply.
Read also | Parliamentary panel reviews drug price peak
Grab everything Industry News,,,,, Bank News and real-time mint updates. download Mint News App every day Market update.
MoreFewer
